Rivaroxaban Fails to Deliver Cardiovascular Protection in Advanced Kidney Disease, Increases Bleeding Risk

Sydney, Australia — A pivotal international clinical investigation has indicated that low-dose rivaroxaban, a widely used anticoagulant, does not provide cardiovascular benefits and, in fact, escalates the danger of major bleeding for individuals grappling with advanced chronic kidney disease (CKD). The findings from the TRACK trial, a comprehensive placebo-controlled study, diverge sharply from the drug's established efficacy in broader patient demographics.

Disappointing Efficacy and Safety Concerns

The TRACK trial represented the inaugural dedicated placebo-controlled effort to evaluate an anticoagulant's ability to safeguard against severe cardiovascular outcomes in advanced CKD patients who face heightened cardiovascular risks. Within this particular patient population, often excluded from major clinical studies, low-dose rivaroxaban did not succeed in lowering the composite risk encompassing cardiovascular death, nonfatal myocardial infarction, stroke, or peripheral artery disease incidents. Over a median observation period of 1.7 years, the incidence of these events stood at 22.6% in the rivaroxaban group compared to 20.7% in the placebo group, yielding a Hazard Ratio (HR) of 1.09 (95% CI 0.).

Furthermore, a significant safety concern emerged regarding major bleeding, the trial's primary safety endpoint. Patients receiving rivaroxaban experienced a considerably higher rate of these events, at 8.8%, versus 6.0% in the placebo cohort, translating to an HR of 1.51 (95% CI 1.). These critical results were presented at the European Renal Association Congress and concurrently published in the esteemed journal *JAMA* by the study investigators, led by Sunil Badve, PhD, from the University of New South Wales Sydney in Australia.

Contrasting with Broader Patient Populations

These outcomes mark a distinct departure from the documented advantages of low-dose rivaroxaban (marketed as Xarelto) in the general population, including individuals with mild to moderate CKD. Previous significant investigations, namely COMPASS and VOYAGER PAD, demonstrated that adding low-dose rivaroxaban to aspirin therapy effectively reduced cardiovascular and thrombotic vascular event rates in patients with established coronary artery disease and peripheral artery disease, respectively. These earlier successes formed the foundation for the drug's FDA approvals for these indications. However, the TRACK trial's data suggest that these benefits do not extend to those with advanced kidney impairment.

Biological Complexities of Advanced CKD

Nisha Bansal, MD, of the University of Washington in Seattle, and Wolfgang Winkelmayer, MD, of Baylor College of Medicine in Houston, provided crucial context in an accompanying editorial. They highlighted that while trials involving broader populations hinted at potential cardiovascular protection from low-dose rivaroxaban, attempting to extrapolate these findings to advanced CKD patients is fraught with challenges. This difficulty arises from the unique biological characteristics of uremia and other specific mechanisms associated with advanced CKD, which concurrently amplify both cardiovascular risk and susceptibility to bleeding.

Intriguingly, a substantial proportion of deaths—42.1%—among the advanced CKD participants in the TRACK study were attributed to sudden cardiac death. This observation, as noted by Bansal and Winkelmayer, introduces doubt regarding the fundamental premise that anticoagulation would be beneficial in this specific context.

Trial Design and Unexpected Challenges

The randomized, double-blind TRACK trial spanned 12 countries across multiple continents. It aimed to enroll 1,900 participants over three years but faced unforeseen hurdles. Initiated during the COVID-19 pandemic, the study was ultimately terminated prematurely in August 2025, with fewer than 1,500 patients randomized, following an interim analysis that revealed a lack of efficacy. Another significant factor impacting the study's interpretation was a substantial 28.2% rate of study drug discontinuation.

Badve and his colleagues underscored the implications of their findings, stating, "This trial underscores the need for dedicated cardiovascular outcome trials in people with advanced CKD." They also reported that rivaroxaban did not reduce all-cause mortality, a key secondary outcome, with rates of 25.6% in the rivaroxaban group versus 23.0% in the placebo group (HR 1.14, 95% CI 0.).

Eligible adults included those with CKD stage 4 or 5 not on kidney replacement therapy, as well as individuals with dialysis-dependent kidney failure. Participants also exhibited an elevated risk of cardiovascular events, evidenced by a history of coronary artery disease, nonhemorrhagic and nonlacunar stroke, peripheral artery disease, diabetes, or being 65 years of age or older. Exclusion criteria included mechanical or prosthetic heart valves (excluding bioprosthetic valves), existing indications or contraindications for anticoagulant therapy, and a high bleeding risk, among others.

From 5,979 individuals screened, 1,458 were randomized equally to receive either 2.5 mg of rivaroxaban twice daily or a placebo. The study cohort had an average age of 63.2 years, with women comprising 29.6%. The group was nearly evenly divided between dialysis-dependent and non-dialysis-dependent individuals. Over three-quarters of participants had diabetes, almost half were at least 65 years old, and nearly one in five had coronary artery disease. A high proportion, 93.3%, completed the follow-up period.

Fotoğraf: Blood Thinner's Promise Fails in Advanced Kidney Disease: A Critical New Trial Unveils Risks

Future Research Directions

Despite the current findings, Bansal and Winkelmayer cautioned against entirely dismissing anticoagulation for cardiovascular protection in advanced CKD. They believe the "door certainly" should not be closed. Crucial questions persist regarding which specific patients are most likely to benefit—perhaps those with established cardiovascular disease—and whether alternative oral anticoagulation strategies might prove more effective or safer in carefully selected CKD populations.

They further suggested that the high incidence of sudden cardiac death in the trial necessitates a recalibration of future research. "This observation calls for a strategic pivot in the design of future trials for cardiovascular disease in this population. Future investigations should more directly address the metabolic, inflammatory, and electrophysiological pathways that predominate in advanced CKD," they advised. The pressing need remains evident: cardiovascular disease disproportionately affects individuals with advanced CKD, contributing to nearly half of their fatalities.

Latest Updates on this Story

As breaking news continues to unfold in the realm of advanced kidney disease treatments, researchers are actively pursuing alternative therapeutic strategies following the TRACK trial's outcomes. This latest update emphasizes the ongoing critical need for safer and more effective cardiovascular prevention for this vulnerable patient group, shaping current news discussions on renal health. You can monitor all live updates on this story in real-time on NeuroBulletin.com.

Related Topics

🔹 Advanced Chronic Kidney Disease 🔹 Rivaroxaban Efficacy 🔹 Cardiovascular Risk 🔹 Anticoagulation Therapy 🔹 Bleeding Complications 🔹 Renal Disease Treatment 🔹 Clinical Trial Outcomes 🔹 Sudden Cardiac Death

About NeuroBulletin News

NeuroBulletin.com is your leading independent resource for comprehensive, evidence-based news and insights across neuroscience and brain health. Our coverage of treatments, like those for advanced kidney disease with neurological implications, provides in-depth, objective reporting to keep healthcare professionals and the public informed about the latest research and clinical developments. We aim to present complex topics with clarity and precision, ensuring our readers receive premium, trustworthy information.

Frequently Asked Questions

What was the primary finding of the TRACK trial regarding rivaroxaban?

The TRACK trial found that low-dose rivaroxaban did not reduce the risk of composite cardiovascular outcomes in patients with advanced chronic kidney disease and, significantly, increased their risk of major bleeding events.

Why were patients with advanced CKD historically excluded from other cardiovascular trials?

Patients with advanced chronic kidney disease (CKD) were often excluded from major cardiovascular trials due to their known elevated risk of bleeding and the complex biological differences associated with uremia, which can affect drug efficacy and safety.

How did the TRACK trial's results compare to rivaroxaban's performance in other patient groups?

In contrast to its established benefits in broader patient populations, including those with mild to moderate CKD, where rivaroxaban has shown cardiovascular protection, the TRACK trial revealed no such advantages and increased risks for advanced CKD patients.

What are the implications of these findings for future research and treatment?

The findings necessitate a re-evaluation of treatment strategies for advanced CKD patients and call for future trials to focus on the metabolic, inflammatory, and electrophysiological pathways predominant in this population, rather than solely on anticoagulation for cardiovascular protection.